The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
SOHO 2019 | Beyond ibrutinib and venetoclax, what are other novel targeted therapies for CLL treatment?
Featured:
Jennifer WoyachDuring SOHO 2019 in Houston, US, Dr Jennifer A. Woyach from The Ohio State University (OSUCCC) in Columbus, US, spoke to the Lymphoma Hub about novel targeted therapies for chronic lymphocytic leukemia (CLL) treatment. She gives an overview of small molecule inhibitors of BTK in clinical development, other than ibrutinib, and venetoclax. Those include new covalent and reversible inhibitors, which are more selective and therefore associated with less toxicity but are also able to overcome ibrutinib resistance.
Beyond ibrutinib and venetoclax, what are other novel targeted therapies for CLL treatment?